Vu Gen News Today

26.09.2023 - – A special 510(k), according to FDA guidance, is usually reviewed within 30 days of receipt – – Pure-Vu Gen 4 platform opens up the Upper GI market, reduces the cost-of-goods by approximately 50% and minimizes the need for onsite support to new ... Seite 1

On track to submit planned special 510(k) for Pure-Vu Gen 4 Gastro and Colon to the FDA in Q4 2023;Received system wide approval in the Banner Med...

Company completes corporate reorganization focused on reducing operating costs while supporting key value creation drivers, including seeking key FDA...

Item 7.01. Regulation FD. On May 24, 2022, Motus GI Holdings, Inc. issued a press release announcing positive topline data from the European Union Feasibility Study of the Pure- Vu®... | May 24, 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.